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Background: Acute leukemia is currently the major cause of death in hematological malignancies. Despite the
rapid development of new therapies, minimal residual disease (MRD) continues to occur and leads to poor outcomes.
The leukemia niche in the bone marrow microenvironment (BMM) is thought to be responsible for such MRD
development, which can lead to leukemia drug resistance and disease relapse. Consequently further investigation
into the way in which the leukemia niche interacts with acute leukemia cells (ALCs) and development of strategies
to block the underlying process are expected to improve disease prognosis. Recent studies indicated that galectin-3
(gal-3) might play a pivotal role in this process. Thus we aimed to elucidate the exact role played by gal-3 in this
process and clarify its mechanism of action.
Methods: We used human bone marrow-derived mesenchymal stromal cells (hBM-MSCs) to mimic the leukemia
BMM in vitro, and investigated their effects on drug resistance of ALCs and the possible mechanisms involved, with
particular emphasis on the role of gal-3.
Results: In our study, we demonstrated that hBM-MSCs induced gal-3 up-regulation, promoting β-catenin stabilization
and thus activating the Wnt/β-catenin signaling pathway in ALCs, which is critical in cytotoxic drug resistance of
leukemia. This effect could be reversed by addition of gal-3 short hairpin RNA (shRNA). We also found that up-regulation
of gal-3 promoted Akt and glycogen synthase kinase (GSK)-3β phosphorylation, thought to constitute a cross-bridge
between gal-3 and Wnt signaling.
Conclusions: Our results suggest that gal-3, a key factor mediating BMM-induced drug resistance, could be a
novel therapeutic target in acute leukemia.
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Acute leukemia (AL), mainly consisting of acute myeloid
leukemia (AML) and acute lymphoblastic leukemia (ALL),
is currently the major cause of death in hematological ma-
lignancies, affecting patients of all ages. Despite ongoing
improvements in the outcomes of patients with AL,* Correspondence: hehuang.zju@gmail.com
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stated.only 30%-40% of adult ALL patients achieve long-term,
disease-free survival due to drug resistance and disease
relapse [1,2]. AML is a heterogeneous disease, and a
substantial number of AML patients have quite a low
cure rate even after hematopoietic stem cell transplant-
ation [3,4]. Minimal residual disease (MRD), which is
widely considered an independent prognostic factor and
currently attracts much attention in treatment interven-
tion, has become a vital challenge in the search for a cure
for AL [5-7]. In addition, the leukemia niche is believed to
play a critical role in the development of MRD.s is an Open Access article distributed under the terms of the Creative Commons
/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in
roperly credited. The Creative Commons Public Domain Dedication waiver
zero/1.0/) applies to the data made available in this article, unless otherwise
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vascular bone marrow niche, provides a home for malig-
nant cells and is responsible for disease relapse as well
as treatment resistance. Previous studies have shown
that stromal cells in the bone marrow microenvironment
(BMM) play an important role in leukemia genesis and
progress by secreting various chemicals and contacting
signals [8], for example the axis of VCAM-1/VLA-4 [9],
SDF-1/CXCR4 [10], and Notch [11], as shown in vitro
and in vivo. Since mesenchymal stromal cells (MSCs), an
important component of both the solid and hematologic
tumor microenvironment [12], give rise to different
stromal cell lineages [13]. In our study we used human
bone marrow-derived MSCs (hBM-MSCs) to represent
a relatively homogeneous BMM stromal cell population
with hematopoiesis-supporting capabilities and immune-
regulatory properties.
Galectin-3 (gal-3), a 30-kDa protein without enzymatic
activity, is a member of the β-galactoside-specific lectin
family. Gal-3 exhibits pleiotropic biological functions
especially in tumors. It has roles in cell growth, apop-
tosis, adhesion, tumor angiogenesis, malignant cell
metastasis, cancer-matrix interaction and also cancer
drug resistance [14,15]. Recent evidence revealed that gal-3
was up-regulated in Ph+ chronic myeloid leukemia (CML)
and in pre-B ALL after conditioning with BM stromal
cells [16,17]. Cheng and colleagues [18] reported that in
patients with AML, higher bone marrow LGALS3(gal-3)
gene expression was an independent unfavorable prog-
nostic factor for overall survival.
However, the specific role of gal-3 in BMM-induced
drug resistance of acute leukemia cells (ALCs) has not
yet been investigated. The aim of our study was to iden-
tify the specific mechanism involved. We found that
gal-3 was dramatically up-regulated in hBM-MSC-
conditioned AL cell lines, accompanying activation of
β-catenin signaling. Both gal-3 and β-catenin signaling
were essential in promoting the survival of ALCs when
treated with cytotoxic drugs. We also showed, for the
first time, that gal-3 modulated β-catenin signaling by
regulating GSK-3β phosphorylation and the PI3K/Akt
pathway in hBM-MSC-conditioned ALCs.
Results
hBM-MSCs induce gal-3 expression and drug resistance in
ALCs
Gal-3 was recently reported to be associated with the
promotion of drug resistance in CML by the bone marrow
microenvironment [16]. We therefore examined whether
it also applied to ALCs. We used hBM-MSCs to mimic
the leukemia BMM in vitro and validated the ability of
hBM-MSCs to protect ALCs from cytotoxic drugs such
as IDA and VP-16. Our results showed that when ALCs
were exposed to cytotoxic drugs, hBM-MSCs significantlyaugmented the absolute number of surviving cells.
Apoptotic levels of ALCs were also significantly de-
creased when co-cultured with hBM-MSCs (Figure 1A
and B, P < 0.05). We also examined the expression level
of gal-3 and found that both mRNA and protein level
were up-regulated in all four AL cell lines conditioned
by hBM-MSCs (Figure 1C). To further elucidate the
exact role of hBM-MSC-induced gal-3 up-regulation in
drug resistance of ALCs, we silenced gal-3 in Reh,
Jurkat and Kasumi-1 cells by stable transfection of
gal-3 antisense shRNA. The results showed that gal-3
was knocked down by more than 60% in all three cell
lines (Figure 2A). We found that the apoptotic levels
in gal-3-silenced ALCs increased significantly with or
without IDA, especially in Jurkat and Reh cells, and the
protective effects of hBM-MSCs against IDA were also
weakened (Figure 2B and C). These findings suggest
that gal-3 induced by hBM-MSCs at least partially ex-
plained drug resistance of acute leukemia cells in vitro.
Up-regulation of gal-3 promotes β-catenin stabilization
Gal-3 has been indicated to play a vital role in Wnt
signaling, which is associated with the promotion of
cell cycle progression and cell viability in colon and
pancreatic cancer cells by interacting with β-catenin
[19,20]. Accordingly, we investigated whether this
signaling pathway also played a role in hBM-MSC-
conditioned ALCs. We first analyzed the expression
levels of β-catenin, which showed that the protein level
of β-catenin were dramatically higher after co-culture
with hBM-MSCs, although the mRNA level did not
show much difference (Figures 1C and 3A). This sug-
gested that gal-3 might modulate β-catenin expression
at the post-transcriptional level, perhaps by inhibiting
its degradation. We then verified our hypothesis in
gal-3-shRNA-transfected ALCs. Hardly any β-catenin
up-regulation was observed when ALCs were co-cultured
with hBM-MSCs (Figure 3B). To further investigate the
role of gal-3-stabilized β-catenin in ALC drug resist-
ance, we treated ALCs with ICG-001, a specific Wnt/β-
catenin signaling inhibitor, and found that it dramatically
decreased the protective effect of hBM-MSCs against
the effects of IDA in ALCs (Figure 3C). Thus, this
suggested that hBM-MSC-induced gal-3 promoted β-
catenin stabilization, which was pivotal in drug resistance
of ALCs.
Gal-3 induces β-catenin accumulation and activates target
gene expression of Wnt/β-catenin signaling
We analyzed the target genes of the Wnt/β-catenin
signaling pathway to verify that they were activated in
our co-culture system. The results of qRT-PCR showed
that transcription of cyclin D1, c-myc and survivin
were all up-regulated in hBM-MSC-conditioned Reh
Figure 1 hBM-MSCs protect ALCs against cytotoxic drugs by up-regulation of gal-3 at both the mRNA and protein levels. (A) ALCs were
treated with IDA (25 nM for Reh and Jurkat cells, 20 nM for Sup-B15, 15 nM for Kasumi-1) or VP-16 (250 nM for Reh cells, 200 nM for Sup-B15, 1000 nM
for Jurkat), cultured with or without hBM-MSCs. The relative number of surviving ALCs was analyzed with CCK-8 assay, as indicated. Absorbance of ALCs
cultured alone were defined as 1. (B) The apoptotic level of ALCs treated with IDA or VP-16, cultured with or without hBM-MSCs was determined by
FACS. (C) ALCs cultured with hBM-MSCs expressed higher level of gal-3 and β-catenin, compared with those unconditioned.
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gal-3-silenced cells. Similar findings were also observed
in Kasumi-1 cells (Figure 4A and B). In line with cyclin
D1 expression, the proportion of proliferative cells
increased in hBM-MSC-conditioned ALCs, and this
effect was weakened once gal-3 was knocked down
(Figure 4C). Collectively, these results showed that
hBM-MSCs promoted activation of the Wnt/β-catenin
signaling pathway in ALCs, which was mediated
through gal-3.
Gal-3 stabilizes β-catenin by regulating GSK-3β activity
and PI3K/Akt axis
Since gal-3 promoted β-catenin up-regulation at the pro-
tein but not the mRNA level, this suggested that it acted
by modulating β-catenin at the post-transcriptional level,
perhaps by inhibiting its degradation. To explore the
specific mechanism involved, we assessed the expres-
sion of total and phosphorylated Akt and GSK-3β inhBM-MSC-conditioned ALCs, as previous studies have
shown that PI3K/Akt signaling can promote GSK-3β
phosphorylation which then stabilizes β-catenin [19,20].
Our results showed that increased gal-3 was associated
with increased phosphorylation of GSK-3β, while the total
protein expression remained unchanged (Figure 5A). In
contrast in gal-3 silenced cells, the level of phosphorylated
GSK-3β was not markedly changed even when the cells
were conditioned with hBM-MSCs (Figure 5B). Our re-
sults also showed that up-regulation of β-catenin in ALCs
occurred later than GSK-3β phosphorylation (Figure 5C),
suggesting that gal-3 modulated β-catenin stabilization via
GSK-3β. We also found increased phosphorylation of Akt
in hBM-MSC-conditioned ALCs (Figure 5A). To confirm
this hypothesis we treated the cells with LY294002, a
specific PI3K/Akt signaling inhibitor, and found that
the up-regulation of β-catenin mediated by hBM-MSCs
was decreased (Figure 5D) while gal-3 expression was
not significantly affected. Taken together, these results
Figure 2 Gal-3 is necessary for drug resistance of ALCs induced by hBM-MSCs. (A) ALCs (Reh, Jurkat and Kasumi-1 cells) were transfected
by gal-3 shRNA or vector as control. Western blot and real time PCR analysis of gal-3 in transfected ALCs under different conditions, namely cultured
alone or with hBM-MSCs. (B) The apoptotic levels of transfected ALCs without any cytotoxic drugs. (C) The apoptotic levels of transfected ALCs treated
with IDA at the concentrations described above. Vc: cells transfected with vector; Gal-3i: cells transfected with gal-3 shRNA.
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by promoting phosphorylation of Akt and GSK-3β.
Refractory/relapsed acute leukemia patients express
higher level of gal-3 in bone marrow
Our research in different cell lines confirmed that gal-3
played an important role in hBM-MSC-induced drug
resistance of ALCs in vitro, so we wondered whether it
also applied to AL patients. Intriguingly, we found that
gal-3 was expressed at a higher mRNA level in BM
mononuclear cells from the patients who suffered fromFigure 3 hBM-MSC-induced β-catenin stabilization is essential for the
(A) The transcriptional level of β-catenin in all four cell lines cultured alone
after transfection with gal-3 shRNA or vector, cultured alone or with hBM-M
ICG-001 (5 μM for Reh cells, 10 μM for Jurkat and Kasumi-1) for 30 minutes, th
after exposure to IDA for 48 h.chemotherapy resistance or disease relapse both in AML
and ALL, compared to primary AL patients (Figure 5E,
P < 0.01). In addition, our results also confirmed that
hBM-MSCs activated the gal-3/β-catenin signaling axis
in primary malignant cells from AL patients (Figure 5F).
Discussion
The present study demonstrates that gal-3 is specifically
induced when acute leukemia cells (Reh, Sup-B15, Jurkat,
Kasumi-1 and primary ALCs) are cultured with hBM-
MSCs in vitro. Gal-3-shRNA largely eliminates hBM-drug resistance of ALCs, and is eliminated by gal-3 knockdown.
or with hBM-MSCs. (B) The expression of β-catenin and gal-3 in ALCs
SCs. (C) ALCs, cultured alone or with hBM-MSCs, were pretreated with
en IDA at indicated concentration was added. Apoptosis was measured
Figure 4 Expression of target genes of Wnt/β-catenin signaling are up-regulated in hBM-MSC-conditioned ALCs. (A) The mRNA levels of
Cyclin D1, c-Myc and Survivin expressed in ALCs cultured alone or with hBM-MSCs. (B) The mRNA levels of Cyclin D1, c-Myc and Survivin expressed in
Reh and Kasumi-1 cells after transfection with gal-3 shRNA or vector, cultured alone or with hBM-MSCs. (C) Cell cycle analysis of Reh and Kasumi-1 cells
after transfection with gal-3 shRNA or vector, cultured alone or with hBM-MSCs.
Hu et al. Journal of Hematology & Oncology  (2015) 8:1 Page 5 of 10MSC-induced gal-3 overexpression and reverses its
protective effects against cytotoxic drugs in ALCs.
Thus the induction of gal-3 is one of the pivotal under-
lying mechanisms of hBM-MSC-mediated protection
of ALCs.
In view of the multiple biological functions of gal-3,
we wondered how gal-3 performed its roles, especially in
the leukemia BMM. Recent studies have suggested that
gal-3 activates Wnt/β-catenin signaling in solid tumors,
such as human colon and pancreatic cancer [19,20].
Wnt signaling plays an important role in maintaining
normal hematopoiesis, and its degradation is causatively
involved in the development of leukemia [21-23]. Yang
et al. [24] indicated that Wnt signaling contributed to
bone marrow stromal cell-mediated protection of ALL
cells, which was in accordance with our results. How-
ever, the precise mechanisms involved remained un-
known, especially in regard to the way in which gal-3
affected Wnt/β-catenin signaling between hBM-MSCs
and acute leukemia. Our data were the first to reveal thatgal-3 up-regulated β-catenin at the post-transcriptional
level and activated its downstream signaling in the
hBM-MSC-supported leukemia niche in vitro.
The specific known target genes of Wnt signaling include
c-Myc [25], cyclin D1 [26], Survivin [27], gastrin [28],
MMP-7 [29] and -2 [20], and cyclooxygenase-2 [30], most
of which play an important role in cell survival, growth,
self-renewal and motility. We therefore assessed the
expression of these specific genes and detected
increased transcription level of cyclin D1, survivin and
c-Myc in ALCs conditioned by hBM-MSCs. However,
once gal-3 was silenced, even though the cells were
conditioned by hBM-MSCs, transcription of these
genes was not significantly up-regulated. The increase
in expression of cyclin D1 shown in our results was far
greater than c-Myc and survivin. Lin et al. [31] found
that gal-3 could promote cyclin D1 expression by
enhancing its promoter activity through SP1 and a
cAMP-responsive element in human breast epithelial
cells. It is still unclear whether this also applies to
Figure 5 Gal-3 up-regulation promotes phosphorylation of Akt and GSK-3β, thereby supporting β-catenin stabilization. (A) The protein
level of phosphorylated Akt (Pho-Akt), total Akt (T-Akt), phosphorylated GSK-3β (Pho-GSK-3β), and total GSK-3β (T-GSK-3β) expressed in ALCs cultured
alone or with hBM-MSCs. Increased gal-3 in hBM-MSC-conditioned ALCs was associated with increased phosphorylation of Akt and GSK-3β
while the total protein expression remained unchanged. (B) The protein level of Pho-GSK-3β and T-GSK-3β in gal-3-silenced Kasumi-1 and Reh
cells, cultured alone or with hBM-MSCs. (C) The time-dependent changes of Pho-GSK-3β and β-catenin in hBM-MSC-conditioned Kasumi-1 and
Reh cells. The densitometry data was measured using Quantity One software, calculated as Pho-GSK-3β/T-GSK-3β compared with the level at
0 h. (D) Expression of β-catenin after treatment with LY294002 (25 μM) in hBM-MSC-conditioned Kasumi-1 and Reh cells. (E) The mRNA levels
of gal-3 expressed in AL patients (P < 0.01). We enrolled 40 patients in all, including 13 primary AML, 13 refractory/relapsed AML and 7 primary
ALL, 7 refractory/relapsed ALL. (F) Western blot analysis of gal-3/β-catenin axis in AL patients-derived malignant cells cultured with or without
hBM-MSCs. Data are from one AML and one ALL patients, representative of the patients examined.
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confirm whether there are other mechanisms involved
in gal-3-mediated cyclin D1 expression other than Wnt
signaling in the acute leukemia microenvironment.
Our results illustrated that gal-3 activated target genes of
Wnt/β-catenin pathway (Cyclin D1, c-Myc and Survivin).
However, gal-3 inhibition in ALC itself did not significantly
affect the expression of these genes. This might be due
to the fact that ALCs only expressed limited gal-3
spontaneously. As previous studies have reported,
Wnt/β-catenin pathway was required for leukaemogen-
esis [32] and a high frequency of leukemic cell lines
were able to freely translocate cytosolic β-catenin to
nucleus [33]. So we suggest that gal-3 is not the pre-
dominant regulator of Wnt/β-catenin pathway in ALCs
without stimulation of hBM-MSCs.
We also analyzed the expression of pho-Akt and pho-
GSK-3β in ALCs conditioned by hBM-MSCs, and found
that both pho-Akt and pho-GSK-3β increased before
the accumulation of β-catenin, which was consistent
with previous studies showing that PI3K-activated Aktcan phosphorylate GSK-3β at Ser9, thereby inactivating
GSK-3β and triggering related signaling pathways [34-36].
In addition, Song [19], Kobayashi [20] and their colleagues
reported that PI3K/Akt-inactivated GSK-3β might be the
bridge between gal-3 and Wnt signaling in colon and
pancreatic cancer. Taken together with our results, these
findings suggest that Akt phosphorylation may be the first
step that occurs after hBM-MSC-induced gal-3 up-
regulation in ALCs, which subsequently promotes GSK-
3β phosphorylation and supports β-catenin stabilization.
Interestingly, the phosphorylation levels of β-catenin fluc-
tuated behind GSK-3β after a time-lag, which indicates
there may be a feedback loop between pho-GSK-3β and
β-catenin stabilization.
Our results demonstrate that signals regulated by gal-3
are correlated with cell cycle progression and drug resist-
ance, which may be major effects of leukemia microenvi-
ronments. This suggests the possibility that gal-3 could be
a potential treatment target for acute leukemia, especially
for minimal residual disease maintained by the leukemia
niche. GCS-100, a citrus pectin-derived specific gal-3
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augmenting drug sensitivity in myeloma, large B-cell
lymphoma and B-chronic lymphocytic leukemia [37-40].
Thus GCS-100, targeting the bone marrow microenviron-
ment of acute leukemia, may be an innovative therapeutic
molecule in the near future. Further in vivo researches
and clinical trials are still warranted.
Since gal-3 is expressed in many tissues and cells, we
tested whether hBM-MSCs also expressed gal-3, and
found that they did (data not shown). Liu et al. [41]
showed that human umbilical cord MSCs expressed
gal-3 both on the cell surface as well as in secreted form.
Secreted gal-3 was critical for the immunomodulatory
potency of hUC-MSCs. It was also mentioned that OP9
cells also secreted gal-3 and that some of the gal-3
detected on pre-B ALL cells was of stromal origin [17].
The role of gal-3 derived from stromal cells and the
potential mechanisms involved in its action in leukemia
therefore deserve further study.
Yamamoto, et al. [16] have reported gal-3 is predomin-
antly expressed in CML cells, but not in acute leuke-
mias. Our results showed that hBM-MSCs also induced
the up-regulation of gal-3 in ALCs in vitro. Furthermore,
the expression level of gal-3 in refractory/relapsed AL
patients is predominantly higher than that in primary
ones. This may suggest gal-3 play a pivotal role in the
maintance of MRDs and development of drug resistance.
However, mechanisms about how the leukemic niche
modulates expression of gal-3 remain little understood,
since no mutation of the LGALS3 gene has been
detected. Since epigenetic alterations are important in
development and maintenance of leukemia cells [42], it
is still unknown whether gal-3 is promoted by acti-
vation of its transcription factors, DNA methylation,
histone modifications, or action of non-coding RNAs
which target gal-3 [43].
Conclusions
Collectively, we propose a model (Figure 6) in which
hBM-MSCs induce drug resistance of ALCs by up-
regulation of gal-3 expression. Gal-3 overexpression
reduces β-catenin degradation through the PI3K/Akt
pathway and phosphorylation of GSK-3β. Thus β-catenin
is stabilized and translocated to the nucleus, where it
activates the transcription of its downstream targets,
ultimately leading to drug resistance of ALCs. Thus our
study demonstrates a novel and possibly clinically-
significant role of gal-3 in the bone marrow microenvir-
onment of acute leukemia.
Methods
Cells and drugs
Human acute leukemia cell lines Reh (non-B non-T ALL)
[44], Sup-B15 (B-ALL) [45], Jurkat (T-ALL) [46], andKasumi-1 (AML, FAB M2) [47] were obtained from the
Cell Bank of the Shanghai Institute of Biochemistry and
Cell Biology, Chinese Academy of Sciences. Bone marrow
was collected from healthy adult donors after they
had provided informed consent, and the hBM-MSCs
obtained were cultured in DMEM-low glucose (Gibco/
Life Technologies, Carlsbad, CA, USA) supplemented
with 10% fetal bovine serum (FBS) (Gibco), identified
as described in our previous report [48]. Bone marrow
mononuclear cells, of which more than 90% were ma-
lignant cells, from primary and refractory/relapsed
acute leukemia (non-M3 AML and ALL) patients were
purified by Ficoll-Paque isodensity gradient centrifu-
gation (Tianjing, China). Idarubicin (IDA) and the Wnt
signaling-specific inhibitor ICG-001 were obtained
from Pfizer Inc., (New York, NY, USA) and from
Selleck Chemicals, (Houston, TX, USA), respectively,
and dissolved in phosphate-buffered saline (PBS) and
dimethylsulfoxide (DMSO). Etoposide (VP-16) and the
PI3K/Akt signaling inhibitor Ly294002 were purchased
from Sigma-Aldrich (St Louis, MO, USA), and dis-
solved in DMSO. All of them were stored at −20°C.
Cell culture and co-culture
Reh and Sup-B15 cells were maintained in IMDM
(Gibco) supplemented with 10% FBS (Gibco), while Jurkat
and Kasumi-1 cells were cultured in RPMI-1640 medium
(Gibco) containing 10% FBS (Gibco). Human BM-MSCs
at passage 3 to 7, displaying a homogeneous mesenchymal
immunophenotype and multipotent differentiation poten-
tial, were used for co-culture experiments. They were
seeded into 12- or 6-well plates at a density of 4 × 104/mL.
ALCs were added to the confluent hBM-MSC layer 1-2
days later at a ratio of 10:1. After ALCs adhered to the
hBM-MSC layer, IDA or VP-16 was added. ICG-001 was
added half an hour ahead of cytotoxic drugs. At indicated
times, ALCs were collected, leaving the adherent stromal
layer intact, and washed with PBS for subsequent analyses.
Short hairpin RNA (shRNA) preparation and transfection
The shRNA against gal-3 in a lentiviral vector with
green fluorescent protein, as well as the corresponding
control vector were designed and synthesized by Gene-
Pharma Inc. (Shanghai, China). High-titer lentivirus was
produced in 293 T cells by transfection of the lentiviral
expression vector and packaging vectors, psPAX2 and
pMD2.G (obtained from www.Addgene.org), using a
calcium phosphate cell transfection kit according to
the manufacturer’s instructions (Beyotime Institute of
Biotechnology, Shanghai, China). The lentivirus was
harvested 48 h later, filtered, enriched using 40% poly-
ethylene glycol, and then used to infect acute leukemia
cells. After transfection for 72 h, the efficiency was esti-
mated by evaluation of EGFP expression by fluorescence
Figure 6 Proposed model in which gal-3 mediates Wnt/β-catenin signaling in the BMM-induced drug resistance of AL. hBM-MSCs induce
gal-3 expression in ALCs. Gal-3 mediates Akt phosphorylation, which promotes phosphorylation of GSK-3β and thus decreases its activity. Inactivation
of GSK-3β leads to a reduction in β-catenin degradation. Stabilized β-catenin translocates to the nucleus and activates transcription of its specific target
genes, which ultimately leads to drug resistance in ALCs.
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sequence used in our study was 5′-GTACAATCATCG
GGTTAAA-3′.
CCK-8 assay for cell viability
Cell Counting Kit-8 (CCK-8) was obtained from Dojindo
Laboratories (Kumamoto, Japan). Measurements were
taken 48 h after drug exposure at the indicated concen-
trations. Absorbance was detected at 450/630 nm by a
Benchmark microtiter plate reader (Bio-Rad Laborator-
ies, Hercules, CA, USA). The relative cell viability was
determined by (Aco − cultured −Amedium)/(Acultured alone −
Amedium) × 100 %.
Cell apoptosis and cell cycle analyses
Acute leukemia cells cultured alone or co-cultured with
hBM-MSCs were exposed to IDA or VP-16 at the indi-
cated concentrations for 48 h, then cells were harvested,
washed and resuspended in PBS. Apoptotic cells among
non-transfected ALCs were identified by staining with
Annexin V-FITC/PI (BD Pharmingen, Franklin Lakes, NJ,
USA), while those in transfected ALCs were identified by
staining with Annexin V-PE/7AAD (BD Pharmingen)according to the manufacturer’s instructions. The stained
cells were analyzed by fluorescence activated cell sorting
(FACS) (Beckman Coulter, Brea, CA, USA).
ALCs for cell cycle analyses were collected after 48 h
of co-culture with hBM-MSCs. All cells were stained
using the cell cycle detection kit (KeyGen Biotech. Co.
Ltd., Nanjing, China) and analyzed by FACS. Cells in S
and G2M phases were considered proliferative.
Protein extraction and western blot analyses
Collected cells were lysed in lysis buffer containing
0.5 M Tris-HCl, pH 6.8, 2 mM EDTA, 10% glycerol, 2%
SDS, 5% β-mercaptoethanol and protease inhibitors. Thirty
to fifty micrograms of protein was separated by 10%-12%
sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) and electotransferred onto polyvinylidene
fluoride membranes. The membranes were blocked in 5%
bovine serum albumin (BSA) at room temperature for 2 h,
incubated with primary antibodies overnight at 4°C, and
then incubated with an IRDye secondary antibody (Li-Cor
Biosciences, Lincoln, NE, USA) at room temperature
for 1 h. The following antibodies were used: anti-gal-3
(Epitomics, Abcam, Cambridge, MA, USA), anti-β-catenin,
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MA, USA), anti-pho-GSK-3β, anti-GSK-3β (Abcam). We
also used anti-β-actin antibody (Sigma) as a control. Immu-
noreactive bands were visualized using an Odyssey infrared
imaging system (Li-Cor). Signal intensity was quantified
using Quantity One software (Bio-Rad) when necessary.
RNA isolation and PCR analyses
Total RNA from collected cells was extracted using Tri-
zol reagent (Takara Bio Inc., Shiga, Japan). One thousand
nanograms of total RNA was used in a 2-step quantita-
tive reverse transcription-PCR (Takara). Real time PCR
was performed with the Roche Applied Science LightCy-
cler 480 II Real-Time PCR System using the SYBR Green
gene expression assay (Takara), according to the manufac-
turer’s instructions. The following primer sets were used
(Sangon, Shanghai, China): Gal-3, 5′-GCCTTCCACTTT
AACCCACG-3′ (forward) and 5′-AACCGACTGTCTT
TCTTCCCTTC-3′ (reverse); β-catenin, 5′-CTGAGGAC
AAGCCACAAGATTA-3′ (forward) and 5′-ATCCACCA
GAGTGAAAAGAACG-3′ (reverse); Cyclin D1, 5′-TCT
ACACCGACAACTCCATCC-3′ (forward) and 5′-GCAT
TTTGGAGAGGAAGTGTTC-3′ (reverse); c-Myc, 5′-CC
TCCACTCGGAAGGACTATC-3′ (forward) and 5′-TGT
TCGCCTCTTGACATTCTC-3′ (reverse); Survivin, 5′-CA
CCGCATCTCTACATTCAAGA -3′ (forward) and 5′-CA
AGTCTGGCTCGTTCTCAGT-3′ (reverse); and GAPDH,
5′-AGAAGGCTGGGGCTCATTTG-3′ (forward) and 5′-
AGGGGCCATCCACAGTCTTC-3′ (reverse). Independ-
ent triplicate samples were used in our experiments.
Statistical analyses
Statistical analyses were performed using GraphPad Prism
for Windows version 5.00 (GraphPad Software, San Diego,
CA, USA) and SPSS 20.0. All data were presented as mean
± SD and statistical differences were evaluated using Stu-
dent’s 2-tailed t-test (paired or unpaired, as appropriate)
and Mann-Whitney U test (for data from AL patients). Dif-
ferences were considered statistically significant at P < 0.05.
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